press-releases

 31 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, will present in the following September 2023 conferences.  H.C. […]

 09 Aug, 2023, 16:05 ET  –    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET –    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif., Aug. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate

 03 Aug, 2023, 16:30 ET  CUPERTINO, Calif., Aug. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results

 20 Jul, 2023, 08:00 ET  CUPERTINO, Calif., July 20, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate

 07 Jun, 2023, 06:00 ET  Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial (NCT04563026) investigating larsucosterol

 May 08, 2023, 16:05 ET  – Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET – Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif., May 8, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update.

 May 01, 2023, 19:03 ET  CUPERTINO, Calif., May 1, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023. Monday, May 8 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 

 Apr 27, 2023, 17:11 ET  CUPERTINO, Calif., April 27, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader (“KOL”) event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet

 Apr 25, 2023, 18:45 ET  CUPERTINO, Calif., April 25, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May

 Apr 10, 2023, 06:00 ET  Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023 CUPERTINO, Calif., April 10, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical